Intranasal formulation helps edaravone reach brain: Early study

An into-the-nose (intranasal) formulation of edaravone — the active ingredient in the amyotrophic lateral sclerosis (ALS) medication Radicava — may enhance the medication’s ability to reach brain tissue, according to a recent study. The formulation, which was made by packaging edaravone into tiny carriers called nanoparticles, was found…

Patients Struggle With Life Quality But Hold to Treatments: US Survey

More than half of the people with amyotrophic lateral sclerosis (ALS) responding to a survey were dissatisfied with their quality of life and pessimistic about their future. The U.S.-based survey was conducted by ALS News Today. Nevertheless, the vast majority of respondents reported to be satisfied with their…